Liu E L, Mi R R, Wang D H, Wang L Q, Zhang Y M, Chen W M
Eur J Gynaecol Oncol. 2017;38(2):209-213.
The aim of this study was to explore the effects of neoadjuvant chemotherapy in senile patients with advanced ovarian can- cer and ascites.
One hundred eight senile patients with advanced ovarian cancer and ascites were randomly di- vided into two groups: experimental and control groups. Patients in the experimental group were treated with two courses of intraperitoneal combined with intravenous neoadjuvant chemotherapy, followed by cytoreductive surgery, and six courses of intravenous chemotherapy, while the patients in the control group only received cytoreductive surgery and six to eight courses of intravenous chemotherapy.
The operation duration, blood loss, ideal success rate of cytoreductive surgery, and prognosis of the two groups were then compared. Thirty-eight patients in the experimental group successfully received cytoreductive surgery, accounting for 74.14%, while only 23 patients in the control group received cytoreductive surgery successfully, accounting for 46%, showing signifinificantly less than those in the control group (p < 0.001). However, the median survival and the median progression-free survival showed no statistical difference between the two groups (p > 0.05).
Neoadjuvant chemotherapy can obviously shorten the operation duration, reduce the intraoperative blood loss, and improve the ideal success rate of cytoreductive surgery, but does not obviously improve the prognosis.
本研究旨在探讨新辅助化疗对老年晚期卵巢癌伴腹水患者的影响。
108例老年晚期卵巢癌伴腹水患者随机分为两组：试验组和对照组。试验组患者接受两疗程腹腔联合静脉新辅助化疗，随后进行肿瘤细胞减灭术，以及六疗程静脉化疗，而对照组患者仅接受肿瘤细胞减灭术和六至八疗程静脉化疗。
然后比较两组的手术时间、失血量、肿瘤细胞减灭术的理想成功率和预后。试验组38例患者成功接受肿瘤细胞减灭术，占74.14%，而对照组仅23例患者成功接受肿瘤细胞减灭术，占46%，明显低于试验组（p<0.001）。然而，两组的中位生存期和中位无进展生存期无统计学差异（p>0.05）。
新辅助化疗可明显缩短手术时间，减少术中失血量，提高肿瘤细胞减灭术的理想成功率，但对预后改善不明显。
